Cargando…
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012
Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890909/ https://www.ncbi.nlm.nih.gov/pubmed/27335831 http://dx.doi.org/10.1155/2013/702167 |
_version_ | 1782435182174797824 |
---|---|
author | Macedo, Daniela Amaral, Teresa Fernandes, Isabel Sousa, Ana Rita Costa, Ana Lúcia Távora, Isabel Quintela, António Cortes, Paulo Costa, Luís |
author_facet | Macedo, Daniela Amaral, Teresa Fernandes, Isabel Sousa, Ana Rita Costa, Ana Lúcia Távora, Isabel Quintela, António Cortes, Paulo Costa, Luís |
author_sort | Macedo, Daniela |
collection | PubMed |
description | Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors. |
format | Online Article Text |
id | pubmed-4890909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48909092016-06-22 The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 Macedo, Daniela Amaral, Teresa Fernandes, Isabel Sousa, Ana Rita Costa, Ana Lúcia Távora, Isabel Quintela, António Cortes, Paulo Costa, Luís ISRN Hepatol Review Article Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75–80% of patients present with liver metastases at the time of their diagnosis, and 20%–25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors. Hindawi Publishing Corporation 2013-02-14 /pmc/articles/PMC4890909/ /pubmed/27335831 http://dx.doi.org/10.1155/2013/702167 Text en Copyright © 2013 Daniela Macedo et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Macedo, Daniela Amaral, Teresa Fernandes, Isabel Sousa, Ana Rita Costa, Ana Lúcia Távora, Isabel Quintela, António Cortes, Paulo Costa, Luís The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title |
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title_full |
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title_fullStr |
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title_full_unstemmed |
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title_short |
The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012 |
title_sort | treatment of liver metastases in patients with neuroendocrine tumors in 2012 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890909/ https://www.ncbi.nlm.nih.gov/pubmed/27335831 http://dx.doi.org/10.1155/2013/702167 |
work_keys_str_mv | AT macedodaniela thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT amaralteresa thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT fernandesisabel thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT sousaanarita thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT costaanalucia thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT tavoraisabel thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT quintelaantonio thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT cortespaulo thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT costaluis thetreatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT macedodaniela treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT amaralteresa treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT fernandesisabel treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT sousaanarita treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT costaanalucia treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT tavoraisabel treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT quintelaantonio treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT cortespaulo treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 AT costaluis treatmentoflivermetastasesinpatientswithneuroendocrinetumorsin2012 |